Tech Company Financing Transactions
ReproNovo Funding Round
On 5/21/2025, ReproNovo secured $65 million in Series A investment from AXA IM Alts, Jeito Capital and M Ventures.
Transaction Overview
Company Name
Announced On
5/21/2025
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its pipeline of multiple Phase 2 programs.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Rue de Langallerie 11
Lausanne, 1003
Switzerland
Lausanne, 1003
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
ReproNovo was founded in 2021 by a team with proven expertise in the reproductive medicine and women's health space. With years of immersion in this field, we possess deep knowledge of drug development, regulatory affairs and business development in these therapeutic areas, the treatment landscape and patient needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean Duvall
Chief Financial Officer
Bingmei Hao
Chief Scientific Officer
Joan-Carles Arce
VP - Operations
Heidi Aasted
VP - Regulatory Affairs
Brenda Marczi
VP - Regulatory Affairs
Lise Nielsen
Browse more venture capital transactions:
Prev: 5/21/2025: Filed venture capital transaction
Next: 5/21/2025: Airwallex venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs